Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

G. Nagaraju

View on Semantic Scholar

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

ABSTRACT Cancer remains a critical global health concern due to late detection, drug resistance, and high mortality. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various cancer cells, including those of ovarian, pancreatic, and gastric cancers. Thus, it could be a valuable target for both as a...

Manoj-Kumar Gupta, Ramakrishna Vadde, G. Nagaraju · 0 citations
Review Aug 2026

Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review.

The cellular stress mediator Nrf2 and its negative regulator Keap1 are frequently dysregulated across breast cancer subtypes. As a master regulator of stress-related pathways, the Nrf2/Keap1 complex drives either cytoprotection or cell death, depending on the cellular context. Furthermore, its roles in promoting drug r...

Anuveda Sree Samudrala, G. Nagaraju, RamaRao Malla · 0 citations
Review Aug 2026

From intercellular communication to therapeutic delivery: Mechanistic perspectives of cancer exosomes.

This review details the role of tumor derived exosomes in shaping an immunosuppressive TME, especially their capacity to modulate T-cell function, polarize myeloid cells, and influence immune checkpoint signalling, and discusses emerging therapeutic strategies aimed at intercepting or reprogramming exosomal cargo.

RamaRao Malla, G. Nagaraju · 0 citations
Jul 2026

Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors

The results support IND-enabling studies of ADT-030 as a monotherapy or in combination with standard-of-care treatments for patients with a broad range of RAS-driven cancers, and especially for patients who relapsed after RAS inhibitor treatment.

Xi Chen, D. S. Bandi, G. Nagaraju et al. · 0 citations
Review Aug 2026

Systemic therapy-induced resistance and toxicity in breast cancer: Sensitization and mitigation strategies.

This review uncovers recent updates on acquired resistance mechanisms toward standard-of-care treatments driven by deeply rooted heterogeneity and aggressive nature and helps to identify novel strategies targeting pathways to reverse resistance and reduce toxicity in breast cancer patients.

Anuveda Sree Samudrala, G. Nagaraju, RamaRao Malla · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.